Abstract

TRUE COST ANALYSIS OF ORAL ANTI DIABETIC DRUGS FOR A PERIOD OF FIVE YEARS TAKING CUMULATIVE INFLATION RATE IN TO CONSIDERATION: A PHARMACOECONOMIC STUDY

*Dr. Bheemesh Naidu Mattam, Bodavula Venkata Naga Siva Sai Sandeep, Mounika Akurathi and Sri Poojitha Nutalapati

ABSTRACT

Pharmacoeconomics is defined as “the description and analysis of the cost of the drug therapy to health care system and society. It identifies, measures and compares the cost and consequences of pharmaceutical products and services.[1] In developing countries the cost of the drug therapy is a major hurdle in effective treatment of disease and compliance towards the drug regimen.[2] India is called as “diabetic capital of the world”. It was estimated by international diabetes federation ( IDF ) that round 40.9 million diabetics live in India and would rise to 69.9 million by the year 2025.[3,4] Diabetes is a chronic disorder which requires lifelong treatment and it is causing economic and health burden on patients as well as the health care system. The main reason for this is increasing cost of treatment and prevalence rate of diabetes.[5] Due to diabetes, global health expenditure in the year 2013 was $548 billion which will rise by $79 billion up to 2035.[6] The rise in burden of complications of diabetes is due to poor patient compliance. In developing countries high cost of medication will negatively affect patient’s compliance. Variation among different brands of same drug which was evident from the literature[7,8,9] and also cost related non-adherence, is being frequently observed in chronic diseases like diabetes mellitus.[10] Inflation is the rate at which the general level of prices for goods and services is rising and, consequently, the purchasing power of currency is falling. The present study aims at identifying the true cost variation of oral anti-diabetic drugs over a period of five years taking cumulative inflation rate into consideration.[11]

Keywords: .